Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03588598
Other study ID # SHC014-I-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 7, 2018
Est. completion date December 2019

Study information

Verified date April 2019
Source Nanjing Sanhome Pharmaceutical, Co., Ltd.
Contact Wei Guo
Phone +86025-81066427
Email guoweiyf@sanhome.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.


Description:

This is a phase I, sequential dose escalation followed by cohort expansion study of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory indolent B-cell hematologic malignancies.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 2019
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1.18- 75 years of age.

2.Histologically or cytologically confirmed diagnosis of relapsed or refractory indolent B-cell hematologic malignancies, including but not limited to CLL / SLL, FL (grade 1, 2 or 3a), or MZL.

3.Patients have received at least 1 prior regimen (at least 2 cycles).

4.Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

5.Life expectancy = 3 months.

6.Patients have at least 1 measurable lesion that measures =1.5 cm in a single dimension as assessed by CT or MRI.

7.Adequate organ function, as defined by the following values: ANC=1.0×10^9/L; PLT=50×10^9/L; Hb=80 g/L; TBIL=1.5×ULN; ALT and AST=2.5×ULN; BUN and Cr=1.5×ULN; LVEF=50%; QTcF <450 ms for male, QTcF <470 ms for female;

8.Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose, and female subjects of childbearing potential have a negative pregnancy test at baseline.

9.Subjects did not participate in other clinical trials within 3 months prior to study entry.

Exclusion Criteria:

1. Disease progression after previous treatment with any PI3Kd inhibitors.

2. Had any other anti-tumor treatment within 4 weeks prior to screening (including radiotherapy, chemotherapy, hormone therapy, surgery or targeted therapy).

3. Evidence of central nervous system involvement of the malignancy.

4. Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, uncontrolled pleural effusion and ascites, uncontrolled diabetes, non-infectious pneumonia, and any other severe cardiovascular, respiratory, nervous and mental diseases.

5. Any of the severe heart diseases, including New York Heart Association (NYHA) Class II or greater heart failure, arrhythmias requiring medical treatment, and history of myocardial infarction or unstable angina within 6 months prior to screening.

6. Require any concomitant medication known to prolong the QT interval during the study.

7. Evidence of active bacterial, fungal, or viral infection.

8. Active infection with hepatitis B virus (HBV) (HBsAg positive, or HBsAg negative and HBV-DNA positive), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

9. Use of high-dose glucocorticoids (eg, =20 mg/day prednisone) or other immunosuppressants within 4 weeks prior to study entry.

10. Concomitant use of any strong inhibitors or inducers of CYP3A4.

11. Use of G-CSF or blood transfusion within 7 days before the hematology test at screening.

12. Prior autologous hematopoietic stem cell transplantation within 6 months prior to treatment initiation.

13. History of prior allogeneic hematopoietic stem cell transplantation.

14. Major surgery within 4 weeks prior to treatment initiation.

15. History of a non-lymphoma malignancy in the past five years except for the following: adequately treated cervical carcinoma in situ, local basal cell or squamous cell carcinoma of the skin.

16. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the drug or previous significant bowel resection that would preclude adequate absorption of the study drug.

17. History of hypersensitivity to drugs similar to the study drug or inactive excipients of the study drug.

18. Women who are breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SHC014748M
a selective PI3Kd inhibitor

Locations

Country Name City State
China The First Affiliated Hospital, Zhejiang University Hangzhou Zhejiang
China The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) 1 month
Primary Time to Peak Plasma Concentration(Tmax) 1 month
Primary Peak Plasma Concentration (Cmax) 1 month
Primary Half-life Time(t1/2) 1 month
Primary Area Under the Plasma Concentration Versus Time Curve (AUC) 1 month
Secondary Objective Response Rate (ORR) up to 12 months
Secondary Lymph Node Response (LNR) up to 12 months
Secondary Time to Response (TTR) up to 12 months
Secondary Progression-Free Survival (PFS) up to 12 months
Secondary Duration of Response (DOR) up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06043011 - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Completed NCT02582879 - informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Completed NCT02553304 - Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients
Completed NCT01419691 - Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT01188681 - Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia Phase 1/Phase 2
Recruiting NCT04758975 - Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) Phase 2
Terminated NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Phase 1
Active, not recruiting NCT01976520 - Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Phase 1
Terminated NCT01463852 - A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL) Phase 0
Terminated NCT01203930 - A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL Phase 2
Recruiting NCT02966756 - A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Phase 2
Active, not recruiting NCT05105841 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 2
Recruiting NCT04072458 - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Phase 1
Withdrawn NCT01754870 - Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Active, not recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Recruiting NCT03547115 - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML Phase 1
Active, not recruiting NCT04285567 - A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Phase 3